BST2 and colorectal carcinoma: The result showed that CRC patients of group 1 (IHC score 0–149, n = 61) had 5-year survival rate of 65.57%, better than 46.47% of group 2 (IHC score 150–300, n = 71; p = 0.044, log-rank test; Figure 3), indicating BST2 tissue expression level as a potential prognostic factor of CRC patients.